Joanne Barrett

676 total citations
26 papers, 525 citations indexed

About

Joanne Barrett is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, Joanne Barrett has authored 26 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Joanne Barrett's work include Cystic Fibrosis Research Advances (10 papers), Influenza Virus Research Studies (7 papers) and Bone health and treatments (4 papers). Joanne Barrett is often cited by papers focused on Cystic Fibrosis Research Advances (10 papers), Influenza Virus Research Studies (7 papers) and Bone health and treatments (4 papers). Joanne Barrett collaborates with scholars based in United Kingdom, United States and Switzerland. Joanne Barrett's co-authors include E. Worth, Frieder Bauss, Solomon Epstein, Charles Oo, Albert Dorr, Penelope Ward, Étienne Dumont, Jean‐Yves Reginster, George Hill and Regina Dutkowski and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Clinical Cancer Research and Cochrane Database of Systematic Reviews.

In The Last Decade

Joanne Barrett

25 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joanne Barrett United Kingdom 14 194 156 144 134 92 26 525
Limin Wu China 13 57 0.3× 94 0.6× 108 0.8× 28 0.2× 24 0.3× 48 562
Heike Oberwittler Germany 8 50 0.3× 47 0.3× 89 0.6× 22 0.2× 38 0.4× 10 357
Greg Allison United States 6 48 0.2× 119 0.8× 101 0.7× 116 0.9× 17 0.2× 7 634
M. G. Rinsler United Kingdom 12 37 0.2× 79 0.5× 61 0.4× 35 0.3× 55 0.6× 42 550
Salim Hadad Israel 13 77 0.4× 101 0.6× 43 0.3× 14 0.1× 19 0.2× 32 475
Francesca Lodato Italy 14 77 0.4× 92 0.6× 239 1.7× 9 0.1× 42 0.5× 32 631
D. J. Smith United States 10 39 0.2× 38 0.2× 74 0.5× 40 0.3× 15 0.2× 13 354
Foad Alzoughool Jordan 10 83 0.4× 134 0.9× 43 0.3× 9 0.1× 27 0.3× 26 537
Bijan Keikhaei Iran 13 33 0.2× 95 0.6× 48 0.3× 15 0.1× 21 0.2× 86 632
Anhye Kim South Korea 9 48 0.2× 69 0.4× 63 0.4× 6 0.0× 54 0.6× 40 328

Countries citing papers authored by Joanne Barrett

Since Specialization
Citations

This map shows the geographic impact of Joanne Barrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne Barrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne Barrett more than expected).

Fields of papers citing papers by Joanne Barrett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne Barrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne Barrett. The network helps show where Joanne Barrett may publish in the future.

Co-authorship network of co-authors of Joanne Barrett

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne Barrett. A scholar is included among the top collaborators of Joanne Barrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne Barrett. Joanne Barrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jarosz-Griffiths, Heledd, Lesley Smith, Joanne Barrett, et al.. (2023). Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis. Journal of Cystic Fibrosis. 22(6). 1002–1009. 19 indexed citations
2.
Goffau, Marcus C. de, Andrew Jones, J.L. Whitehouse, et al.. (2023). EPS5.01 Change in gut microbiota following elexacaftor/tezacaftor/ivacaftor (ETI) therapy: preliminary analysis. Journal of Cystic Fibrosis. 22. S49–S49. 2 indexed citations
3.
White, H., Andrew Jones, Joanne Barrett, et al.. (2023). Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis. Journal of Cystic Fibrosis. 22(2). 275–281. 9 indexed citations
4.
5.
Barrett, Joanne, et al.. (2021). Perception, experience and relationship with food and eating in adults with cystic fibrosis. Journal of Human Nutrition and Dietetics. 35(5). 757–764. 7 indexed citations
6.
Egan, Helen, et al.. (2020). Mindfulness moderates the relationship between emotional eating and body mass index in a sample of people with cystic fibrosis. Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity. 26(5). 1521–1527. 26 indexed citations
7.
Barrett, Joanne, et al.. (2017). Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 3. CD009422–CD009422. 32 indexed citations
8.
Brown, Catherine, et al.. (2015). Physical Activity in Adults with Cystic Fibrosis Receiving Intravenous Antibiotics in Hospital and in the Community§. The Open Respiratory Medicine Journal. 9(1). 15–21. 5 indexed citations
9.
Barrett, Joanne, et al.. (2014). Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews. CD009422–CD009422. 9 indexed citations
10.
Niu, Huifeng, Petra Goelzer, Ruediger Rueger, et al.. (2010). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression. The Journal of Clinical Pharmacology. 50(12). 1397–1405. 8 indexed citations
11.
Niu, Huifeng, Ruediger Rueger, Jonathan Deutsch, et al.. (2009). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. Clinical Cancer Research. 15(23). 7368–7374. 30 indexed citations
12.
Pillai, Gopal S, et al.. (2006). Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. International Journal of Clinical Pharmacology and Therapeutics. 44(12). 655–667. 14 indexed citations
13.
Reginster, Jean‐Yves, Katie Wilson, Étienne Dumont, Bernard Bonvoisin, & Joanne Barrett. (2005). Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Postmenopausal Women: Results from the Monthly Oral Pilot Study. The Journal of Clinical Endocrinology & Metabolism. 90(9). 5018–5024. 45 indexed citations
14.
Kurowski, Michael, Charles Oo, Hugh Wiltshire, & Joanne Barrett. (2004). Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses. Clinical Drug Investigation. 24(1). 49–53. 15 indexed citations
15.
Barrett, Joanne, E. Worth, Frieder Bauss, & Solomon Epstein. (2004). Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update. The Journal of Clinical Pharmacology. 44(9). 951–965. 123 indexed citations
16.
Oo, Charles, et al.. (2003). Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. International Journal of Pharmaceutics. 257(1-2). 297–299. 22 indexed citations
17.
Oo, Charles, Joanne Barrett, Albert Dorr, Baolian Liu, & Penelope Ward. (2002). Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin. Antimicrobial Agents and Chemotherapy. 46(6). 1993–1995. 20 indexed citations
18.
Oo, Charles, et al.. (2002). Lack of pharmacokinetic interaction between the oral anti‐influenza neuraminidase inhibitor prodrug oseltamivir and antacids. British Journal of Clinical Pharmacology. 54(4). 372–377. 19 indexed citations
19.
Oo, Charles, Joanne Barrett, George Hill, et al.. (2001). Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children. Pediatric Drugs. 3(3). 229–236. 67 indexed citations
20.
Barrett, Joanne, et al.. (1996). Bioequivalence of Selegiline HCL: Guidance for a “Highly Variable” Drug. Clinical Pharmacology & Therapeutics. 59(2). 206–206. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Limin Wu Breakdown of academic impact, for papers by Heike Oberwittler Breakdown of academic impact, for papers by Greg Allison Breakdown of academic impact, for papers by M. G. Rinsler Breakdown of academic impact, for papers by Salim Hadad Breakdown of academic impact, for papers by Francesca Lodato Breakdown of academic impact, for papers by D. J. Smith Breakdown of academic impact, for papers by Foad Alzoughool Breakdown of academic impact, for papers by Bijan Keikhaei Breakdown of academic impact, for papers by Anhye Kim
Rankless by CCL
2026